|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
1999-5-26
|
|
pubmed:abstractText |
In vitro data have indicated that tamoxifen (> 2.5 uM) significantly enhances the cytotoxic effect of doxorubicin in hepatocellular carcinoma (HCC) cells. This clinical study was conducted to examine whether tamoxifen, at a dose sufficient to result in a plasma concentration of more than 2.5 uM, may improve the therapeutic efficacy of doxorubicin in patients with advanced HCC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0172-6390
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1955-60
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9951847-Adult,
pubmed-meshheading:9951847-Aged,
pubmed-meshheading:9951847-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9951847-Carcinoma, Hepatocellular,
pubmed-meshheading:9951847-Disease Progression,
pubmed-meshheading:9951847-Dose-Response Relationship, Drug,
pubmed-meshheading:9951847-Doxorubicin,
pubmed-meshheading:9951847-Drug Administration Schedule,
pubmed-meshheading:9951847-Drug Synergism,
pubmed-meshheading:9951847-Female,
pubmed-meshheading:9951847-Follow-Up Studies,
pubmed-meshheading:9951847-Humans,
pubmed-meshheading:9951847-Liver Neoplasms,
pubmed-meshheading:9951847-Male,
pubmed-meshheading:9951847-Middle Aged,
pubmed-meshheading:9951847-Prospective Studies,
pubmed-meshheading:9951847-Survival Rate,
pubmed-meshheading:9951847-Tamoxifen,
pubmed-meshheading:9951847-Treatment Outcome
|
|
pubmed:articleTitle |
Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Internal Medicine, National Taiwan University Hospital, Taipei.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
